Page last updated: 2024-08-16

temozolomide and cyc 202

temozolomide has been researched along with cyc 202 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Feelders, RA; Hofland, LJ; Lacroix, A; Newell-Price, J; Nieman, LK; Pivonello, R	1
Babu, PP; Narne, P; Pandey, V; Ranjan, N	1

Reviews

1 review(s) available for temozolomide and cyc 202

Article	Year
Advances in the medical treatment of Cushing's syndrome. The lancet. Diabetes & endocrinology, 2019, Volume: 7, Issue:4 Topics: ACTH Syndrome, Ectopic; ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenal Gland Neoplasms; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cabergoline; Cushing Syndrome; Dopamine Agonists; ErbB Receptors; Gefitinib; Hormones; Humans; Imidazoles; Isoquinolines; Molecular Targeted Therapy; Pituitary ACTH Hypersecretion; Pyrazoles; Pyridines; Receptors, Glucocorticoid; Roscovitine; Somatostatin; Temozolomide; Tretinoin	2019

Article

Year

Advances in the medical treatment of Cushing's syndrome.

The lancet. Diabetes & endocrinology, 2019, Volume: 7, Issue:4

Topics: ACTH Syndrome, Ectopic; ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenal Gland Neoplasms; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cabergoline; Cushing Syndrome; Dopamine Agonists; ErbB Receptors; Gefitinib; Hormones; Humans; Imidazoles; Isoquinolines; Molecular Targeted Therapy; Pituitary ACTH Hypersecretion; Pyrazoles; Pyridines; Receptors, Glucocorticoid; Roscovitine; Somatostatin; Temozolomide; Tretinoin

2019

Other Studies

2 other study(ies) available for temozolomide and cyc 202

Article	Year
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Roscovitine effectively enhances antitumor activity of temozolomide in vitro and in vivo mediated by increased autophagy and Caspase-3 dependent apoptosis. Scientific reports, 2019, 03-21, Volume: 9, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Caspase 3; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Glioma; Humans; Platelet Endothelial Cell Adhesion Molecule-1; Rats; Rats, Wistar; Roscovitine; Temozolomide; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2019

Article

Year

Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.

Chemical research in toxicology, 2010, Volume: 23, Issue:1

Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010

Roscovitine effectively enhances antitumor activity of temozolomide in vitro and in vivo mediated by increased autophagy and Caspase-3 dependent apoptosis.

Scientific reports, 2019, 03-21, Volume: 9, Issue:1

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Caspase 3; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Glioma; Humans; Platelet Endothelial Cell Adhesion Molecule-1; Rats; Rats, Wistar; Roscovitine; Temozolomide; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2019